What is Leerink Partnrs’ Estimate for Quanterix Q1 Earnings?

Quanterix Co. (NASDAQ:QTRX) – Equities researchers at Leerink Partnrs issued their Q1 2026 EPS estimates for Quanterix in a report released on Tuesday, January 7th. Leerink Partnrs analyst P. Souda anticipates that the company will post earnings of ($0.25) per share for the quarter. The consensus estimate for Quanterix’s current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix’s Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.13) EPS and Q4 2026 earnings at ($0.16) EPS.

Separately, TD Cowen lifted their price target on shares of Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research note on Wednesday, November 13th.

Quanterix Price Performance

Quanterix stock opened at $11.73 on Wednesday. The stock has a market cap of $451.89 million, a price-to-earnings ratio of -11.17 and a beta of 1.33. The firm has a 50-day moving average of $12.02 and a two-hundred day moving average of $12.69. Quanterix has a 1 year low of $9.87 and a 1 year high of $29.70.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC bought a new stake in shares of Quanterix in the 3rd quarter valued at about $60,000. Peapack Gladstone Financial Corp purchased a new position in Quanterix during the third quarter valued at approximately $131,000. SG Americas Securities LLC bought a new position in Quanterix in the third quarter worth approximately $139,000. Canada Pension Plan Investment Board purchased a new stake in Quanterix during the second quarter worth $140,000. Finally, Hsbc Holdings PLC boosted its position in Quanterix by 34.7% during the 2nd quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock valued at $164,000 after acquiring an additional 3,279 shares in the last quarter. 86.48% of the stock is currently owned by institutional investors.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.